Vimarsana
Biggest News Aggregation in the World

Page 7 - Minor Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Minor Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Minor Use Today - Breaking & Trending Today

Jaguar Health, Inc.: Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Vimarsana News

Jaguar Health, Inc.: Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

The Canalevia.com website, a resource for veterinarians and dog owners, is now liveCanalevia-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval

Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Vimarsana News

Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
Jaguar Health, Inc.: Jaguar Health Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs - Vimarsana News

Jaguar Health, Inc.: Jaguar Health Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs

By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri treeSAN FRANCISCO, CA / ACCESSWIRE

Jaguar Health : Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs - Vimarsana News

Jaguar Health : Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs

By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree ... | December 22, 2021

Jaguar Health, Inc.: Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA - Vimarsana News

Jaguar Health, Inc.: Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA

By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri treeSAN FRANCISCO, CA / ACCESSWIRE